市場調查報告書
商品編碼
1298599
2023-2028年按產品、應用、終端用戶和地區分類的無針給藥技術市場Needle-free Drug Delivery Technology Market by Product, Application, End User, and Region 2023-2028 |
2022年,全球無針給藥技術市場規模達到41.8億美元。展望未來,IMARC Group預計,到2028年,市場規模將達到57.2億美元,在2023-2028年期間表現出5.22%的成長率(CAGR)。慢性病發病率的上升,老年人口的增加,以及最近雷射供電的無針注射技術(NFIT)的發展,代表了推動市場的一些關鍵因素。
無針給藥技術是指不使用傳統針頭給病人注射藥物的方法。它包括微噴頭噴射器、經皮貼劑、吸入器、一次性筒狀注射器、鼻腔噴劑和超音波。它們被廣泛用於疫苗接種、胰島素輸送、疼痛管理、激素治療,以及治療過敏、癌症、呼吸系統疾病和其他慢性疾病。與傳統的針式給藥系統相比,無針給藥技術可以減少疼痛,最大限度地減少不適和焦慮,增強便利性,提高病人的依從性,允許劑量客製化,並防止受傷和感染的風險。它還能提供更快的藥物輸送,並有助於加強藥物吸收,盡量減少併發症,提高治療效果。無針給藥技術也是生態友好的,因為它最大限度地減少了危險廢物的產生,減少了製造排放,並消除了產品處置的需要。
糖尿病、癌症、克隆氏症、多發性硬化症、關節炎、骨質疏鬆症和心血管疾病(CVDs)等慢性病的發病率不斷上升,是推動市場成長的主要因素之一。無針給藥技術被廣泛用於向慢性病患者提供胰島素和藥物,沒有疼痛和不適感,從而改善治療效果,降低感染風險,並提高患者的生活品質。此外,廣泛採用技術來改善用藥的依從性,增加藥物吸收,提高治療效果,並儘量減少與針頭有關的併發症,正成為另一個成長誘因。此外,最近開發的以雷射為動力的無針注射技術(NFIT),利用基於雷射的系統,將藥物的微觀射流高精度地註入皮膚,正在積極地影響著市場的成長。此外,在獸醫護理中擴大使用技術,以人道和無壓力的方式為動物注射疫苗、藥物和麻醉,有利於市場的成長。除此之外,政府為促進採用無針給藥系統和支持先進技術的發展而實施的各種計劃,也為市場成長創造了積極的前景。其他因素,包括由於傳染病發病率的增加而導致的疫苗需求的上升,老年人口的增加,醫療保健行業的顯著成長,廣泛的研究和開發(R&D)活動,以及消費者對無針給藥技術的好處認知的提高,預計將推動市場的成長。
請注意,這只代表部分公司的名單,完整的名單已在報告中提供。
The global needle-free drug delivery technology market size reached US$ 4.18 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.72 Billion by 2028, exhibiting a growth rate (CAGR) of 5.22% during 2023-2028. The escalating prevalence of chronic diseases, the increasing geriatric population, and the recent development of laser-powered needle-free injection technology (NFIT) represent some of the key factors driving the market.
Needle-free drug delivery technology refers to a method of administering medications to patients without using traditional needles. It includes micronozzle jet injectors, transdermal patches, inhalers, disposable cartridge injectors, nasal sprays, and ultrasound waves. They are widely used for vaccinations, insulin delivery, pain management, hormone therapy, and treating allergies, cancer, respiratory conditions, and other chronic diseases. As compared to traditional needle-based delivery systems, needle-free drug delivery technology reduces pain, minimizes discomfort and anxiety, enhances convenience, improves patient compliance, allows dosage customization, and prevents the risk of injuries and infections. It also offers faster medication delivery and aids in enhancing drug absorption, minimizing complications, and increasing treatment effectiveness. Needle-free drug delivery technology is also eco-friendly as it minimizes hazardous waste generation, reduces manufacturing emissions, and eliminates the need for product disposal.
The escalating prevalence of chronic diseases, such as diabetes, cancer, Crohn's disease, multiple sclerosis, arthritis, osteoporosis, and cardiovascular diseases (CVDs), is one of the primary factors driving the market growth. Needle-free drug delivery technology is widely used to deliver insulin and medications to chronic disease patients without pain and discomfort, which improves treatment outcomes, reduces the risk of infections, and enhances patients' quality of life. Furthermore, the widespread technology adoption to improve medication adherence, increase drug absorption, enhance treatment effectiveness, and minimize complications associated with needles is acting as another growth-inducing factor. Additionally, the recent development of a laser-powered needle-free injection technology (NFIT), which utilizes a laser-based system to blast microscopic jets of drugs into the skin with high precision, is positively influencing the market growth. Moreover, increasing technology utilization in veterinary care to administer vaccines, medications, and anesthesia to animals in a humane and stress-free manner is favoring the market growth. Apart from this, the implementation of various government initiatives to promote the adoption of needle-free drug delivery systems and support the development of advanced technologies are creating a positive outlook for the market growth. Other factors, including rising demand for vaccines due to the increasing prevalence of infectious diseases, increasing geriatric population, significant growth in the healthcare industry, extensive research and development (R&D) activities, and growing consumer awareness regarding the benefits of needle-free drug delivery technology, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global needle-free drug delivery technology market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on product, application, and end user.
Inhaler
Jet Injector
Novel Needles
Transdermal Patch
Others
The report has provided a detailed breakup and analysis of the needle-free drug delivery technology market based on the product. This includes inhaler, jet injector, novel needles, transdermal patch, and others.
Vaccine Delivery
Pain Management
Insulin Delivery
Others
A detailed breakup and analysis of the needle-free drug delivery technology market based on the application has also been provided in the report. This includes vaccine delivery, pain management, insulin delivery, and others.
Hospitals and Clinics
Homecare Settings
Research Laboratories
Academics
Others
A detailed breakup and analysis of the needle-free drug delivery technology market based on the end user has also been provided in the report. This includes hospitals and clinics, homecare settings, research laboratories, academics, and others.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for needle-free drug delivery technology. Some of the factors driving the North America needle-free drug delivery technology market included the increasing prevalence of chronic diseases, the implementation of various government initiatives, and rapid technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global needle-free drug delivery technology market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Akra Dermojet, Antares Pharma Inc. (Halozyme Therapeutics Inc.), Crossject, Mika Medical Co., PharmaJet, Portal Instruments Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.